# Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

> **NCT02397382** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 16 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Midazolam
- **DRUG:** Warfarin
- **DRUG:** Omeprazole
- **DRUG:** Dextromethorphan
- **DRUG:** Caffeine

## Key facts

- **NCT ID:** NCT02397382
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-18
- **Primary completion:** 2016-08-31
- **Final completion:** 2016-08-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02397382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02397382, "Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02397382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*